# Effect of Limosilactobacillus Reuteri DSM 17648 in Healthy Adults Reporting Upper Gastrointestinal Discomfort

> **NCT07163637** · NA · RECRUITING · sponsor: **Novozymes A/S** · enrollment: 324 (estimated)

## Conditions studied

- Healthy Participants
- Upper Gastrointestinal Discomfort

## Interventions

- **DIETARY_SUPPLEMENT:** Limosilactobacillus reuteri DSM 17648
- **DIETARY_SUPPLEMENT:** Placebo

## Key facts

- **NCT ID:** NCT07163637
- **Lead sponsor:** Novozymes A/S
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-08
- **Primary completion:** 2026-03-31
- **Final completion:** 2026-03-31
- **Target enrollment:** 324 (ESTIMATED)
- **Last updated:** 2025-09-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07163637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07163637, "Effect of Limosilactobacillus Reuteri DSM 17648 in Healthy Adults Reporting Upper Gastrointestinal Discomfort". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07163637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*